Biocept (BIOC) Tops Q4 EPS by 15c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. DOX
3. DUOL
4. CVS
5. BKNG
6. SWKS
7. ANET
8. FLYW
9. AMGN
10. SMCI

Go back to Biocept (BIOC) Tops Q4 EPS by 15c, Revenues Miss

Pre-Open Stock Movers 03/26: (ALDX) (BBBY) (BIOC) Higher; (CCL) (MYOK) (RCL) Lower (more...)

March 26, 2019 9:28 AM EDT

Today's Pre-Open Movers

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 66.8% HIGHER; announced positive results from the Phase 3 ALLEVIATE Trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of... More

Maxim Group Starts Biocept (BIOC) at Buy

March 26, 2019 7:37 AM EDT

Maxim Group analyst Jason McCarthy initiates coverage on Biocept (NASDAQ: BIOC) with a Buy rating and a price target of $3.00.

We are initiating coverage of Biocept with a Buy rating and $3 price target. Biocepts Target Selector is a liquid biopsy platform which, in addition to providing actionable data based on circulating tumor DNA (ctDNA) analysis, incorporates... More